Metabolic profile of amphetamine and methamphetamine following administration of the drug famprofazone

Journal of Analytical Toxicology

Volumn 27, Issue 7, 2003, Pages 479-484

  Greenhill, Brandy ^a   Valtier, Sandra ^b   Cody, John T ^c,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b 59th Medical Wing ^*  (United States)

^c US Army Medical Department Center & School   (United States)

^d AMEDD C and S MCCS HMP PA Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIPYRETIC ANALGESIC AGENT; BUTYRIC ACID DERIVATIVE; CREATININE; DRUG METABOLITE; FAMPROFAZONE; METHAMPHETAMINE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DERIVATIZATION; DRUG EXCRETION; DRUG METABOLISM; ENANTIOMER; GAS CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; MONITORING; NORMAL HUMAN; PH; QUANTITATIVE ANALYSIS; RELATIVE DENSITY;

EID: 0141459503     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/27.7.479     Document Type: Conference Paper

References (16)

1. J.T. Cody. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J. Occup. Environ. Med. 44(5): 435-450 (2002).
2. Gewodin Geistlich (Package Insert). Vol. 930369/9308/BB. Gewo Chemie GmBH, Baden-Baden, Germany, 1995.
3. J.T. Cody. Enantiomeric composition of amphetamine and methamphetamine derived from the precursor compound famprofazone. Forensic Sci. Int. 80: 189-199 (1996).
4. H.S. Shin, B.B. Park, S.N. Choi, J.J. Oh, C.P. Hong, and H. Ryu. Identification of new urinary metabolites of famprofazone in humans. J. Anal. Toxicol. 22: 55-60 (1998).
5. Y. Yoo, H. Chung, and H. Choi. Urinary methamphetamine concentration following famprofazone administration. J. Anal. Toxicol. 18: 265-268 (1994).
6. E.S. Oh, S.K. Hong, and G.I. Kang. Plasma and urinary concentrations of methamphetamine after oral administration of famprofazone to man. Xenobiotica 22(3): 377-384 (1992).
7. H.S. Shin, J.S. Park, P.B. Park, and S.J. Yun. Detection and identification of famprofazone and its metabolite in human urine. J. Chromatogr. B 661 (2): 255-261 (1994).
8. M. Neugebauer. Some new urinary metabolites of famprofazone and morazone in man. J. Pharm. Biomed. Anal. 2(1): 53-60 (1984).
9. H.S. Shin. Stereoselective metabolism of famprofazone in humans: N-dealkylation and beta- and p-hydroxylation. Chirality 9(1): 52-58 (1997).
10. Mandatory guidelines for federal workplace drug testing programs. Fed. Regist. 59(110): 29908-29931 (1994).
11. S. Valtier and J.T. Cody. Evaluation of internal standards for the analysis of amphetamine and methamphetamine. J. Anal. Toxicol. 19: 375-380 (1995).
12. D. Hensley and J.T. Cody. Simultaneous determination of amphetamine, methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA), and methylenedioxyethylamphetamine (MDEA) enantiomers by GC-MS. J. Anal. Toxicol. 23: 518-523 (1999).
13. Cutoff Concentrations as specified in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. November 1, 2001, Substance Abuse and Mental Health Services Administration, Rockville, MD.
14. 14C] methamphetamine in man, the guinea pig and the rat. Biochem. J. 129: 11-22 (1972).
15. A.H. Beckett and M. Rowland. Urinary excretion kinetics of methylamphetamine in man. J. Pharm. Pharmacol. 17(Suppl.): 109S-114S (1965).
16. M. Neugebauer, A. Khedr, N. El-Rabbat, M. El-Kommos, and G. Saleh. Stereoselective metabolic study of famprofazone. Biomed. Chromatogr. 11: 356-361 (1997).